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For decades, advances in endocrinology were characterized
by a process in which hormones were first identified based
upon their physiologic roles and then purified, often from
vast quantities of biologic material. This purified material
was then used to identify the receptors through which the
hormone signaled. In this classic progression, science moved
from physiology to cellular signaling. More recently, tech-
nological advances have turned this process literally inside
out. With the advent of rapid complementary deoxyribonu-
cleic acid screening, multiple genes were identified whose
predicted structure revealed a steroid hormone receptor.
This produced a group of so-called orphan receptors, whose
cognate ligands and physiologic role remained completely
obscure (1).
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Peroxisome proliferator-activated receptors (PPARs)
were one such group of orphan receptors, with three
different isoforms: PPAR-alpha (-), PPAR-gamma (-),
and PPAR-delta (-) (2). Chemical screening led to the
serendipitous discovery of compounds that uniquely bound
to and activated PPAR isoforms (2). For PPAR-, the first
PPAR identified, these compounds, when fed to rodents,
increased the size and number of the subcellular peroxisome
organelle (3). This induction of “peroxisome proliferation”
also gave rise to the term PPAR, a name as imprecise as it
is unwieldy, given the apparent absence of peroxisome
proliferation in humans (4). More clinically relevant was the
unexpected discovery that thiazolidinediones (TZDs), a
class of synthetic compounds under study for their glucose-
lowering effects, did so by binding to PPAR- (2). This fit
with burgeoning data establishing PPAR- as a ligand-
activated nuclear receptor highly expressed in fat and critical
to adipogenesis, glucose homeostasis, and lipid metabolism
(5). The TZD-targeted responses included increased ex-
pression of the glucose transporter GLUT4, possibly un-
derlying its clinical effects (6). Three TZDs have come to
clinical use as antidiabetic insulin sensitizers (2,7). The first
TZD released, troglitazone (ReZulin, Warner-Lambert
Co., Morris Plains, New Jersey), was ultimately withdrawn
because of cases of irreversible liver toxicity. Subsequent
TZDs, pioglitazone (Actos, Takeda Chemical Industries
Ltd., Osaka, Japan) and rosiglitazone (Avandia, Glaxo-
SmithKline, New York, New York), have lacked such
toxicity despite significant patient exposure and study. The
TZDs have been a welcome addition to the armamentarium
against the increasing onslaught of type 2 diabetes mellitus,
a disease characterized by insulin resistance. Agents that
sensitize patients to insulin, as opposed to those compen-
sating for insulin resistance by increasing insulin levels,
would seem a more directed approach to the problem.
Insulin sensitizers as antidiabetic agents are also appeal-
ing for their possible cardiovascular benefits, offering hope
for definitive evidence that improved glucose control de-
creases cardiovascular complications (8). Arguably the best
evidence to date for decreased cardiovascular outcomes
through a diabetes intervention comes from trials with
metformin, an insulin sensitizer albeit with a PPAR-
independent mechanism of action (9). Cardiovascular out-
comes with TZDs are under intense study. Cardiovascular
benefits with TZD use could come from two distinct effects.
Certainly, the improved insulin sensitivity, lower circulating
glucose levels, and better lipids seen with TZDs might
indirectly limit atherosclerosis or its complications. Alter-
natively, if PPARs were expressed in vascular and inflam-
matory cells, then PPAR activation could have direct effects
on atherosclerosis by inducing or repressing specific relevant
target genes (10). In fact, extensive data from many groups
now establish PPAR-, -, and - expression throughout
the vasculature and in many inflammatory cells, as well as an
ever-expanding list of PPAR target genes involved in
vascular biology (11,12). Most, but not all, of these data
suggests activation of PPAR- and -, the isoforms tar-
geted by synthetic agonists in current clinical use, would
decrease atherosclerosis and/or inflammation. In vivo stud-
ies support this possibility. Several PPAR- agonists have
been shown to limit atherosclerosis in various mouse models
of atherosclerosis (12). Moreover, clinical data in humans
on surrogate end points of atherosclerosis also are suggestive
of potential TZD benefits. Thus far, PPAR- agonists
reportedly decrease circulating levels of C-reactive protein
(CRP) (13), CD40 ligand (14,15), and MMP-9 (13,16). In
small studies, PPAR- agonists also decreased carotid
intimal:medial thickening (17,18) and in-stent restenosis.
In this issue of the Journal, Sidhu et al. (19) extend similar
surrogate approaches to ask whether PPAR- agonists
might improve markers of endothelial responses as well as
more general measures of inflammation and atherosclerosis.
Peroxisome proliferator-activated receptors are expressed in
the endothelium (20), a cellular element in the vascular wall
now recognized as a dynamic organ integrally involved in
vascular responses (21). In these studies, the authors gave an
escalating amount of rosiglitazone (4 mg then 8 mg) or
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placebo to a small group of patients (46 in each arm) with
angiographically established coronary artery disease for just
12 weeks (19). Rosiglitazone treatment significantly de-
creased CRP levels as well as a group of endothelial markers,
including von Willibrand factor and E-selectin. Fibrinogen
was also decreased, as were indicators of insulin sensitivity.
Theoretically, such TZD benefits in the general population
might derive from improved glucose parameters as well as
direct transcriptional effects. One intriguing aspect of this
study is the possible circumvention of these confounding
possibilities: these individuals did not have diabetes. Inter-
estingly, these various parameters were improved even while
low-density lipoprotein (LDL) and triglyceride levels were
modestly increased in the active therapy arm (113 vs. 102
mg/dl and 130 vs. 108 mg/dl, respectively).
This article, even with the limitations of studies like it,
touches upon a host of intriguing issues moving increasingly
to the center of the cardiologist’s field of vision. The
extensive laboratory work suggesting PPAR- activation as
a potential target for ameliorating diabetes/insulin resistance
and atherosclerosis continues to be translated to clinical
settings, facilitated by the clinical use of TZDs. Although
much of the attention on gene therapy has focused on
introducing exogenous genes, the possibility exists, fueled by
expanding insight into cellular transcriptional machinery,
for transcriptionally active drugs to have clinical effects
through altered gene expression. Indeed, such effects on
gene expression may contribute to responses with other
agents like statins (22) or estrogens. Did the changes seen by
Sidhu et al. (19) result from PPAR- activation and altered
gene expression? The answer is not known, especially
because less insulin resistance was seen even among this
presumably nondiabetic cohort. If improved insulin sensi-
tivity were at work, this result would be consonant with the
move in preventive cardiology toward earlier intervention in
the course of this disease. Both atherosclerosis and diabetes
have proven themselves as chronic processes arising over
decades (23,24). Waiting for patients to cross a defined and
often-arbitrary threshold before initiating therapy is a prac-
tice derived from necessity but defined by our current
insight or lack thereof. It is also potentially dangerous.
Many first myocardial infarcts are fatal (25). Most such
individuals would have as much evidence of atherosclerosis
the day before their event as they did at its onset, absent
perhaps an intact fibrous cap (24). Such issues are perhaps
even more obvious in diabetes given clinical markers—high
triglycerides/low high-density lipoprotein (HDL), central
obesity, hypertension—that suggest underlying insulin re-
sistance, future conversion to diabetes, and their concomi-
tant cardiovascular risk. C-reactive protein itself may predict
the development of diabetes (26). The TZDs may offer a
unique opportunity for earlier intervention or their use in
nondiabetics, given their lack of induced hypoglycemia (7).
Larger studies will hopefully resolve whether earlier inter-
vention translates into benefits in atherosclerosis, diabetes,
or both.
As studies expand the list of potential TZD benefits, it
will remain important to consider if any potential untoward
effects became apparent. Although Sidhu et al. (19) did find
the TZD to be generally well-tolerated even among these
“nondiabetic” individuals, rosiglitazone did modestly in-
crease LDL and triglyceride levels. Although these changes
were perhaps easily modifiable by titrating other drugs, that
is, statins, they remain potentially proatherogenic responses.
The modest LDL increases observed previously with TZDs
may be offset by a more buoyant, less-dense, less-
atherogenic LDL particle (27). Different TZDs may also
have different lipid effects (28), perhaps as a result of unique
ligand/receptor interactions. Both rosiglitazone and piogli-
tazone have been reported to increase HDL levels (27,28),
at times to an extent rivaling HDL intervention trials; no
changes in HDL were evident here. The increase in weight
seen with TZDs represents another potentially undesirable
side effect. Interestingly, some suggest this may predict
clinical response and/or involve a shift in fat from visceral to
subcutaneous depots (29). Of note, one TZD-induced
fat-derived cytokine, adiponectin, may limit inflammation
(30), whereas a TZD-repressed protein, resistin, may pro-
mote insulin resistance (31). Some weight gain may also
derive from fluid retention and edema (32), fostering
concerns over TZD-precipitated heart failure. This has led
to avoiding TZDs when the ejection fraction is low or
clinical heart failure is present. The extent to which this
edema is due to the known vasodilatory effects of these
drugs versus more worrisome left-sided failure with elevated
pulmonary capillary wedge pressures remains unclear. Some
retrospective data suggest a significant element of the
former (33). This issue is under study and requires resolu-
tion, especially given recent data that many heart failure
patients take insulin sensitizers (34) and because this prob-
lem, if unfounded or minor, may preclude some patients
from access to the other benefits of TZDs.
No doubt TZDs will continue to be the subject of
ongoing interest in terms of their clinical and especially
cardiovascular effects. Several factors will drive this. One
issue is simple numbers. The incidence of diabetes among
Americans is increasing in seemingly direct proportion to
the expanding waistline of the population (35). Especially
troubling is the trend towards adolescents who are present-
ing with classic insulin-resistant, obesity-related type 2
diabetes mellitus (36). A second issue is science. Biologic
insight into PPARs and other orphan nuclear receptors is
rapidly increasing in parallel with the pursuit of many novel
PPAR agonists now in various stages of development (37).
These later-generation PPAR agonists include single com-
pounds capable of activating both PPAR- and -, dan-
gling the prospect of a drug that treats dyslipidemia like
PPAR-–activating fibrates while sensitizing to insulin-like
PPAR-–activating TZDs (38,39). A third force is the
unmet clinical need for cardiovascular risk interventions that
add something to the impressive but not curative effects of
statins among people with diabetes. Agents that either delay
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or prevent the onset of diabetes would also fall into this
category; a possibility already raised for TZDs (40). One
final potent stimulus to this arena may be synergism. Two of
the most dominant recent trends in cardiovascular science—
atherosclerosis as an inflammatory disease and diabetes as a
vascular disorder—seem to unite in the study of PPAR-
and the basic and clinical consequences of its activation.
Early studies of the effects of TZD on surrogate markers
like CRP and adhesion molecules support PPAR- as a
therapeutic target for inflammation. It remains to be seen in
TZD studies in larger numbers of patients if a clinical
cardiovascular benefit results from hitting this target.
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